Physician profile
Moises Bucay
NPI 1285614529
$9,400.40
in general payments reported to CMS, 2019-2025
43 companies · $2,605 in 2025
The $2,605 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $261 · 2021: $1,204 · 2022: $1,263 · 2023: $1,594 · 2024: $1,477 · 2025: $2,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,820 · Travel and Lodging: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,820.14 |
| Travel and Lodging | $855.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,305.37 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Cardiosight Reader |
| Novartis Pharmaceuticals Corporation | $1,859.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $791.11 | 2019-2024 | Xarelto, Spravato |
| Boston Scientific Corporation | $631.00 | 2019-2025 | Cds - Mct/Cem Monitoring, Watchman Flx, Bodyguardian |
| Merck Sharp & Dohme LLC | $576.77 | 2019-2025 | Verquvo, Belsomra |
| Pfizer INC. | $552.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.11 | 2021-2025 | Jardiance |
| Amgen INC. | $254.84 | 2019-2025 | Evenity, Repatha |
| E.R. Squibb & Sons, L.L.C. | $224.42 | 2019-2025 | Camzyos, Eliquis |
| Biotronik INC. | $183.29 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $175.71 | 2020-2025 | Brilinta, Farxiga |
| Recor Medical INC | $174.11 | 2025 | Paradise Ultrasound Renal Denervation System |
| Esperion Therapeutics, INC. | $135.29 | 2020-2023 | Nexletol |
| Abiomed | $133.30 | 2021-2023 | Impella |
| Alnylam Pharmaceuticals INC. | $107.32 | 2020-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Bucay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.